Denise Myshko is the editor of Formulary Watch.
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
CVS Caremark Switches Up Biosimilar Coverage in 2024
As part of updates to its standard formulary, CVS Caremark has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Specialty Therapies Offering Incremental Benefit Shouldn’t Be Added to Clinical Pathways, Hertler Says